<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01611805</url>
  </required_header>
  <id_info>
    <org_study_id>114472</org_study_id>
    <nct_id>NCT01611805</nct_id>
  </id_info>
  <brief_title>Japanese Phase I of GSK1605786</brief_title>
  <official_title>A Placebo-Controlled, Four-Period Crossover, Single Ascending Oral Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of the CCR9 Receptor Antagonist GSK1605786 in Japanese Healthy Male Subject</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an double-blind, single dose, four-period, crossover study in Japanese healthy male
      volunteers to assess the pharmacokinetics and safety/tolerability of single doses of
      GSK1605786A. Approximately 24 subjects will receive three treatments of 250, 500, and 1000mg
      GSK1605786 under fasted conditions or 500mg after food intake plus placebo in a dose
      ascending crossover design. Serial pharmacokinetic samples will be collected following each
      dose and safety assessments will be performed. The pharmacokinetics and dose proportionality
      of GSK1605786 after single oral doses of GSK1605786 at the dose levels of 250mg, 500mg and
      1000 mg under fasted conditions will be assessed. In addition, a comparison will be made
      between the pharmacokinetics of GSK1605786 under fed and fasted conditions.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 22, 2010</start_date>
  <completion_date type="Actual">October 6, 2010</completion_date>
  <primary_completion_date type="Actual">October 6, 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma concentration</measure>
    <time_frame>up to 72h post dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse envents</measure>
    <time_frame>up to 72h post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signe</measure>
    <time_frame>up to 72h post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical laboratory</measure>
    <time_frame>up to 72h post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12 lead ECG</measure>
    <time_frame>up to 72h post dose</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Crohn's Disease</condition>
  <arm_group>
    <arm_group_label>GSK1605786 250mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Opaque Swedish orange body and cap.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Opaque Swedish orange body and cap.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK1605786 500mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Opaque Swedish orange body and cap.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK1605786 1000mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Opaque Swedish orange body and cap.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK1605786 500mg in fed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Opaque Swedish orange body and cap.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK1605786</intervention_name>
    <description>Opaque Swedish orange body and cap.</description>
    <arm_group_label>GSK1605786 500mg in fed</arm_group_label>
    <arm_group_label>GSK1605786 500mg</arm_group_label>
    <arm_group_label>GSK1605786 1000mg</arm_group_label>
    <arm_group_label>GSK1605786 250mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK1605786 Placebo</intervention_name>
    <description>Opaque Swedish orange body and cap.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy Japanese as

          -  Japanese defined as being born in Japan, having four ethnic Japanese grandparents,
             holding a Japanese passport or identity -Male between 20 and 55 years of age
             inclusive, at the time of signing the informed consent.

          -  Body weight =&gt;50kg and BMI within the range 18.5 - 25 kg/m2 (inclusive).

        Exclusion Criteria:

        - Known coeliac disease or positive serologic testing for anti-tTG antibodies (required to
        screen for undiagnosed celiac disease)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <link>
    <url>https://gsk-clinicalstudyregister.com/study/114472?search=study&amp;search_terms=114472#rs</url>
    <description>Results for study 114472 can be found on the GSK Clinical Study Register.</description>
  </link>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 12, 2012</study_first_submitted>
  <study_first_submitted_qc>May 31, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2012</study_first_posted>
  <last_update_submitted>June 13, 2017</last_update_submitted>
  <last_update_submitted_qc>June 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

